Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62037
Title: | 犬淋巴瘤預後與CD10、Bcl-6、MUM1和Bcl-2表現之相關性 The Correlation between Prognosis and Expression of CD10, Bcl-6, MUM1 and Bcl-2 in Canine Lymphomas |
Authors: | Yao-Chun Chien 簡耀君 |
Advisor: | 劉振軒(Chen-Hsuan Liu) |
Keyword: | 犬淋巴瘤,免疫化學染色,CD10,Bcl-6,MUM1,Bcl-2,預後, Canine lymphoma,immunohistochemistry,CD10,Bcl-6,MUM1,Bcl-2,prognosis, |
Publication Year : | 2013 |
Degree: | 碩士 |
Abstract: | 淋巴瘤是犬最常見的惡性腫瘤之一,形態學上與人類非何杰金氏淋巴瘤 (non-Hodgkin’s lymphoma)具有高度類似性。依照世界衛生組織分類法,瀰漫性大型B細胞淋巴瘤(diffuse large B cell lymphoma; DLBCL)為犬最常見的淋巴瘤。此外,濾泡型淋巴瘤(follicular lymphoma)、被套細胞淋巴瘤(mantle cell lymphoma)、邊緣區型淋巴瘤(marginal zone lymphoma)、與T區域型淋巴瘤(T-zone lymphoma)之臨床表徵屬於緩慢型淋巴瘤(indolent lymphoma)。
DLBCL在人類可區分為類生發中心B細胞型(germinal center B-cell-like)與類活化B細胞型(activated B-cell-like)兩種分子學亞型(molecular subtypes),前者之生物標記包含了CD10和Bcl-6,而MUM1與Bcl-2則為後者之標記。病人罹患GCB型DLBCL具有顯著較佳總存活率。 本研究為探討在犬淋巴瘤中,這四個蛋白質之免疫組織化學染色表現程度與預後之相關性。在收集的102例病例中,B細胞淋巴瘤占59例、T細胞型占41例、以及無顯著分型之淋巴瘤占2例,其中DLBCL為最常見的淋巴瘤類型。針對具有完整臨床資訊之53病例,進行CD10、Bcl-6、MUM1和Bcl-2之免疫組織化學染色。結果顯示,Bcl-2表現弱之淋巴瘤具有顯著較短的總存活時間(overall survival time),而CD10、Bcl-6、MUM1之表現皆與預後無關。此外,本研究亦證實世界衛生組織分類法之診斷與預後有顯著相關,其中緩慢型淋巴瘤不但總存活時間較非緩慢型(non-indolent)淋巴瘤長,且皆具有中等至強的Bcl-2表現程度。本研究的結果顯示,犬DLBCL並無法以CD10、Bcl-6、MUM1和Bcl-2區分為不同的分子學亞型,然而在所有種類的淋巴瘤中,Bcl-2具有預估臨床預後之潛力,其機制仍需進一步的研究加以探討。 Lymphoma is one of the most common malignancies in dogs. Canine lymphoma bears a morphological resemblance to non-Hodgkin’s lymphoma in the human. Diffuse large B-cell lymphoma (DLBCL), according to the World Health Organization (WHO) classification, is the most common form of canine lymphoma. Furthermore, indolent lymphomas that are characterized by a slowly progressive clinical course include follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and T-zone lymphoma. Human DLBCLs can be sorted into two molecular subtypes: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL. CD10 and Bcl-6 are biomarkers for GCB-DLBCL, while ABC-DLBCL is representative of MUM1 or Bcl-2 expression. Patients diagnosed with GCB-DLBCL show a significant better overall survival rate than those diagnosed with ABC-DLBCL. The present study is to investigate the correlation between prognosis and expression of CD10, Bcl-6, MUM1 and Bcl-2 in canine lymphomas. A total of 102 cases met the inclusion criteria, with 59 of B-cell derivation, 41 of T-cell derivation, and 2 of null-cell derivation. DLBCL was the most common diagnosis based on the WHO criteria. Immunohistochemical stain for CD10, Bcl-6, MUM1 and Bcl-2 was performed on a total of 53 cases with a complete medical and follow-up record. The results indicated that none of the markers had a correlation with prognosis with the exception of Bcl-2. Bcl-2 expression had a significantly positive correlation with overall survival time. Moreover, indolent lymphomas not only showed prolonged overall survival over non-indolent lymphomas, but also were characterized by moderate or strong levels of Bcl-2 expression. In conclusion, we did not find molecular subtypes of canine DLBCL via CD10, Bcl-6, MUM1 and Bcl-2 expression. Among these four markers, only Bcl-2 had a potential prognostic value of canine lymphomas. The mechanism of Bcl-2 remains to be determined, though. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62037 |
Fulltext Rights: | 有償授權 |
Appears in Collections: | 分子暨比較病理生物學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-102-1.pdf Restricted Access | 8.9 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.